Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers

Lymphocyte-activating gene-3 (LAG-3, CD223) is the third inhibitory receptor targeted for immunotherapy. Several clinical trials investigating the use of interventions targeting LAG-3 are underway. The exact signaling mechanism downstream of LAG-3 is largely unknown, especially in breast cancer. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seokwon, Kim, Jee Yeon, Lee, So Jeong, Kwon, Soon Wook, Jung, Ho Jin, Jung, Se Jin, Kim, Kyung Bin, Choi, Kyung Un, Lee, Chang Hun, Huh, Gi Yeong, Kim, Ahrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678028/
https://www.ncbi.nlm.nih.gov/pubmed/34918659
http://dx.doi.org/10.1097/MD.0000000000028057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678028/
https://www.ncbi.nlm.nih.gov/pubmed/34918659
http://dx.doi.org/10.1097/MD.0000000000028057

Ejemplares similares